Melinta Therapeutics

Melinta Therapeutics is an American pharmaceutical company that specializes in the development and commercialization of novel antibiotics to treat serious bacterial infections. The company was founded in 2000 and is headquartered in Morristown, New Jersey.

History

Melinta Therapeutics was originally established as Rib-X Pharmaceuticals in 2000 by a group of scientists from Yale University. The company was rebranded as Melinta Therapeutics in 2013. Over the years, Melinta has developed a robust pipeline of antibiotics to address the growing problem of antibiotic resistance.

Products

Melinta Therapeutics' product portfolio includes several antibiotics that have been approved by the Food and Drug Administration (FDA). These include Baxdela (delafloxacin), Vabomere (meropenem and vaborbactam), Orbactiv (oritavancin), and Minocin (minocycline) for Injection. These drugs are used to treat a variety of serious bacterial infections, including skin and skin structure infections, complicated urinary tract infections, and bacterial pneumonia.

Research and Development

Melinta Therapeutics is committed to the research and development of new antibiotics to combat the global threat of antibiotic resistance. The company's proprietary drug discovery platform, the Antibiotic Resistance Breaker (ARB), is designed to enhance the potency and spectrum of existing antibiotics and to develop new antibiotics that are effective against drug-resistant bacteria.

Financial Information

Melinta Therapeutics is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol MLNT. The company's financial performance is reported in its annual 10-K report and quarterly 10-Q report.

See Also

• Pharmaceutical industry in the United States
• Antibiotic resistance
• Drug discovery

   This article is a pharmacology-related stub. You can help WikiMD by expanding it!